How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
3 citations3 with PMIDValidation: 0%3 supporting / 0 opposing
✓For(3)
No supporting evidence
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theoretical Analysis: C1q-Driven Synaptic Pruning in Alzheimer's Disease
Key Molecular Mechanisms
C1q initiates the classical complement cascade, binding directly to synapses in an activity-independent manner—distinct from developmental pruning, which selectively eliminates less-active terminals. This pathway operates through sequential molecular events:
C1q deposition: Upregulated by astrocytes and neurons in AD brain, binding exposed phosphatidylserine on stressed synapses (Hong et al. 2016, PMID 27339137)
C3 convertase formation: C1q triggers C4/C2 cleavage, genera
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
The hypothesis presents an elegant mechanistic framework linking amyloid oligomers to complement-driven synaptic loss, with therapeutic translation via ANX005. While the molecular pathway is biologically plausible and supported by experimental data, the theoretical analysis contains significant weaknesses that warrant scrutiny.
1. Causal Direction Remains Unresolved
The hypothesis assumes C1q upregulation drives synaptic loss in AD. However, C1q has established roles in synaptic maintenance and pr
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Translation Assessment: C1q as a Therapeutic Target in AD
Druggability — Favorable but Complex
C1q is a well-characterized target with validated biology. ANX005 (Anixa Biosciences), a monoclonal antibody against C1q, represents the primary clinical asset. It completed a Phase 1 study (NCT04592302) in healthy volunteers establishing initial safety and pharmacokinetic profiles. The company subsequently explored ALS (NCT05037964), but AD-specific development remains early-stage. Preclinical data in mouse models demonstrated reduced synaptic loss and preserved cognition, with
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"hypothesis_title": "Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Decline in Alzheimer's Disease","synthesis_summary": "The C1q-mediated synaptic pruning hypothesis presents a mechanistically compelling framework linking amyloid oligomers to complement-driven synapse loss through microglial phagocytosis via C3-CR3 signaling. While the molecular pathway is biologically plausible and supported by strong preclinical data including Hong et al. 2016, significant concerns remain about causal direction and whether complement activation represents a primary driver or a secondary
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
Loading history…
⚖️ Governance History
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions,
Elo penalties, or pause grants affect this subject.